Oral Metagenomic Biomarkers in Rheumatoid Arthritis

Sponsor
University of Florida (Other)
Overall Status
Completed
CT.gov ID
NCT02544334
Collaborator
United States Department of Defense (U.S. Fed), VA Medical Center-Gainesville (U.S. Fed)
92
2
39.2
46
1.2

Study Details

Study Description

Brief Summary

Rheumatoid Arthritis (RA) is a chronic and potentially severe autoimmune disease affecting 2 million in the United States. The role of environmental factors in modulating autoimmunity pathogenesis has been clearly described and yet the specific mechanisms of action remain poorly understood. A growing body of evidence implicates microbiota of mucosal surfaces in the development of autoimmune disorders. Various studies have clearly linked RA to periodontal disease. The latter is linked to the red-complex that includes the oral bacterium Porphyromonas gingivalis. And yet there has not been a systematic analysis of the oral microbiota in RA to determine whether there are specific markers for P. gingivalis (and other oral bacteria) that are linked to RA.

In this study, the investigators will characterize oral microbial composition (microbiome) and gene content (metagenome) of DNA isolated from oral samples obtained from patients with (i) early stage RA prior to biologics treatments and (ii) subsets of RA patients who are responsive or unresponsive to anti-TNF-alpha therapy. The innovative aspect of this study is going beyond the identification of oral bacterial species, to the level of strains and genes that are associated with these groups. The overall hypothesis is that oral microbial variation exists between individuals that influences development of autoimmunity and autoimmune disease.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Dental Plaque
  • Other: Multi-dimensional health assessment questionnaire (MDHAQ)
  • Other: Saliva Collection

Detailed Description

This is a multi-disciplinary research study with five investigators from different, yet complementary, disciplines to establish this new collaboration. There is a high translational potential for information gained from this project based on the collaboration of a rheumatologist, a dentist, oral biologists, and infectious disease experts with expertise in immunology, microbiology, and genomics. In brief, RA participants will be recruited by the rheumatologist. A total of 100 participants will be recruited for two groups to be studied; one group of subjects with RA and the other group will be healthy controls. These two groups will be divided into the following groups for participation in the study: Group 1: will consist of 25 RA adult subjects who have not been treated with biologics which will be compared to 25 healthy controls from age-matched members of the same household. Group 2 will consist of 25 RA adult subjects responsive to first line anti-TNF therapy which will be compared to 25 subjects of the same age and sex with RA who are resistant to two or more TNF antagonists. The participants will be scheduled for a research study visit at the University of Florida Dental Clinic Research Unit. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.

The supragingival will be subjected to deep sequencing in the genomics lab. To test two specific aims: 1) testing the hypothesis that oral microbiome profiles based on 16S RNA data are associated with the development of RA or with the response to a specific therapy, and 2) testing the hypothesis that the specific genes, variants, and functional capabilities (metagenome) are associated with RA or with therapeutic response. Upon completion of this pilot study, the investigators will have systematically identified bacterial biomarkers (e.g. species, subspecies, genes) that correlate with RA and may serve as potential targets for disease treatment. These markers may be developed into new drug targets for RA therapy in future studies.

Study Design

Study Type:
Observational
Actual Enrollment :
92 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Oral Metagenomic Biomarkers in Rheumatoid Arthritis
Study Start Date :
May 1, 2016
Actual Primary Completion Date :
Aug 8, 2019
Actual Study Completion Date :
Aug 8, 2019

Arms and Interventions

Arm Intervention/Treatment
RA - naïve to biologics

This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.

Procedure: Dental Plaque
All participants will have dental plaque removed from different tooth surfaces for supragingival.

Other: Multi-dimensional health assessment questionnaire (MDHAQ)
The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
Other Names:
  • MDHAQ
  • Other: Saliva Collection
    All participants will have a saliva collection.

    Healthy Controls

    This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.

    Procedure: Dental Plaque
    All participants will have dental plaque removed from different tooth surfaces for supragingival.

    Other: Saliva Collection
    All participants will have a saliva collection.

    RA responsive to anti-TNF

    This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.

    Procedure: Dental Plaque
    All participants will have dental plaque removed from different tooth surfaces for supragingival.

    Other: Multi-dimensional health assessment questionnaire (MDHAQ)
    The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
    Other Names:
  • MDHAQ
  • Other: Saliva Collection
    All participants will have a saliva collection.

    RA non responsive to anti-TNF

    This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.

    Procedure: Dental Plaque
    All participants will have dental plaque removed from different tooth surfaces for supragingival.

    Other: Multi-dimensional health assessment questionnaire (MDHAQ)
    The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
    Other Names:
  • MDHAQ
  • Other: Saliva Collection
    All participants will have a saliva collection.

    Outcome Measures

    Primary Outcome Measures

    1. Oral microbiome will be catalogued in each group for their association with RA. [Day 1]

      A Wilcoxon rank-sum test will be computed on each profile to identify differential metagenomic gene content between each pair of groups (RA patients and controls). The potential microbial functional roles of the KEGG orthologues and eggnog orthologue groups markers in the oral microbiota of RA patients will also be assessed. All results will be corrected for multiple testing using a false discovery rate approach.

    2. Metagenomic analyses will be performed to find oral bacteria markers between the groups. [18 months]

      A Wilcoxon rank-sum test will be computed on each profile to identify differential metagenomic gene content between each groups.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • with at least 10 natural uncrowned teeth (excluding third molars) must be present.
    Exclusion Criteria:
    • have less than 10 teeth;

    • have been treated with antibiotics within the past 3 months, including patients that require antibiotic prophylaxis prior to dental treatment;

    • are immune compromised individuals (HIV, AIDS, immuno-suppressive drug therapy);

    • participate in another clinical study involving the use of dental products one week prior to the start of the washout period or during the study period; and

    • are unwilling or unable to provide informed consent and follow the collection instructions.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Florida College of Dentistry-Periodontics Gainesville Florida United States 32610
    2 Randall Malcom VA Medical Center Gainesville Florida United States 32611

    Sponsors and Collaborators

    • University of Florida
    • United States Department of Defense
    • VA Medical Center-Gainesville

    Investigators

    • Principal Investigator: Michael R Bubb, MD, University of Florida
    • Principal Investigator: Edward K Chan, Ph.D., University of Florida

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Florida
    ClinicalTrials.gov Identifier:
    NCT02544334
    Other Study ID Numbers:
    • IRB201500286
    • 11712325
    • 12.420
    First Posted:
    Sep 9, 2015
    Last Update Posted:
    Aug 12, 2019
    Last Verified:
    Aug 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Florida
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 12, 2019